Venture Capital

NovoEd passes acquisition test
Occupational learning tool developer NovoEd, based on research at Stanford, has been bought by Devonshire Investors after raising $4.8m of series A capital in 2014.
Oh My Green tosses together $20m
Stanford-Start X Fund has put its weight behind Oh My Green's seed round, which also attracted a host of venture capital firms.
Amgen inserts $66m into Oxford Nanopore
Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.
Berkeley Lights attracts Nikon for $95m round
The cell biology technology developer, based on UC Berkeley research, took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.
Locate Bio pinpoints $660,000 round
Mercia Technologies has returned to back Locate Bio's pursuit of orthopaedic therapies based on research at University of Nottingham.
Kahoot loots funding at $300m valuation
Datum Invest has led a $15.3m round for educational game platform Kahoot, which is the result of research at Norwegian University of Technology and Science.
Indiana duo meet BioCrossroads for $9m fund
University of Notre Dame and Indiana University have both backed a $9m seed fund aimed at supporting local businesses in life sciences, health IT and agricultural biosciences.
Edison Partners welcomes Rutgers to $365m fund
Rutgers University was among a string of limited partners for the growth equity firm's ninth fund, which was oversubscribed from its $300m target.

Other News

Cardialen jumpstarts $17m series B
The George Washington spinout had previously raised $4.1m in equity for its low-voltage implantable cardiac defibrillator.
Turnitin marks Gradescope for acquisition
UC Berkeley’s SkyDeck accelerator has secured an exit as schoolwork assessment technology developer Gradescope was acquired by Turnitin.
Garrison rallies for $30m
Cybersecurity technology developer Garrison has received $5m from IP Group after being backed by Touchstone in 2015 and 2017.
Mission Secure shields $8m for series A
University of Virginia Seed Fund returned to back industrial cybersecurity spinout Mission Secure in a round co-led by Chevron Technology Ventures and Energy Innovation Capital.
Rgenix generates $40m series C
The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.
Gotham goes to $54m in series A
Cornell spinout Gotham Therapeutics has come out of stealth with a series A round co-led by SR One, Versant Ventures and Forbion.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Big deal: Roche derives MS treatment
Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg

Login

Not yet subscribed?

See your subscription offers here